PURSUIT Platelet IIb-IIIa in Unstable angina: Receptor Suppression Using Integrilin? (eptifibatide) Therapy
PURSUIT Death or MI composite within 30 days
% Patients with composite events
16.2%
12.8%
Angiography within 72 hrs
3.4% ? (p=0.005*)
16.8%
11.8%
5.5%
1.8%
33.5%
18.4%
PCI within 72 hrs
5.0% ? (p=0.01*)
MI prior to PCI within 72 hrs
3.7% ? (p=0.001*)
CABG within 72 hrs
15.1% ? (p=0.001*)
* Post-randomization analysis
PURSUIT Death or MI composite at 30 days in patients undergoing PCI within 2, 4, or 6 hours of randomization
% Patients with composite events
16.5%
9.1%
16.1%
9.7%
15.1%
9.5%
PCI within 2 hours
7.4% ?
PCI within 4 hours
6.4% ?
PCI within 6 hours
5.6% ?
(n=79) (n=66)
(n=118) (n=103)
(n=139) (n=127)
Not powered for statistical analysis
PURSUIT Death or MI composite within 30 days in transferred patient population
% Patients with composite events
23%
18%
21%
15%
29%
26%
Transferred population
5% ?
U.S. transferred population
6% ?
Non-U.S. transferred population
3% ?
(n=429)
(n=310)
(n=119)
Not powered for statistical analysis.
PURSUIT Death or MI composite within 30 days based upon time from onset of symptoms
% Patients with composite events
17.5%
14.7.%
15.8%
13.5%
15.4%
14.0%
< 6 hrs
2.8% ?
6-12 hrs
2.3% ?
> 12 hrs
1.4% ?
PURSUIT Impact on myocardial muscle preservation
All MIs
13.6%
12.6%
% Patients with major bleeding
p = 0.001
62.4%
57.5%
* Defined as intracranial hemorrhage or overt bleeding with ? hemoglobin ? 5g/dL or hematocrit ? 15%.
PURSUIT Major TIMI bleeding in patients undergoing CABG within 72 hours*
% Patients with major bleeding
64%
62%
* Defined as intracranial hemorrhage or overt bleeding with ? hemoglobin ? 5g/dL or hematocrit ? 15%.
PURSUIT Major TIMI* bleeding in patients undergoing CABG within 2 hours of discontinuation of eptifibatide infusion